



Artisan Sustainable Emerging Markets Fund

MONTHLY
Commentary

Investor Class: ARTZX

As of 31 August 2020

Commentary

Our portfolio has outperformed the MSCI EM Index QTD. Most global markets have moved ahead strongly QTD due in part to a combination of improving economic data, more stimulus from governments and central banks and encouraging early-stage trial results for multiple COVID-19 vaccines. So far this quarter, EM equities have generally fared better than DM equities, with the US as the notable exception. China and Taiwan have been the benchmark's top contributors while Thailand and Turkey have been the leading detractors.

Polyus and Taiwan Semiconductor Manufacturing (TSMC) have been among our top relative contributors QTD. Shares of Polyus, a Russian gold miner, have moved up with the price of gold. The negative economic effects of COVID-19 and concerns that unprecedented monetary and fiscal stimulus will eventually spur inflation have stimulated demand for precious metals. Polyus is among the lowest cost producers globally and attractive in terms of production growth compared to its gold mining peers.

Shares of TSMC, the world's largest dedicated chip foundry, have benefited from Intel, a US-based chip designer and manufacturer, pushing back the release date of its seven nanometer semiconductors and its admission that it may look to partner with another foundry to produce its chips. If Intel decides to outsource any of its chip manufacturing, we believe TSMC would be the most logical partner given its existing ability to manufacture seven nanometer chips and dominance in the market.

Among our leading relative detractors QTD have been Sino Biopharm and China Traditional Chinese Medicine. Sino Biopharm is a diversified pharmaceutical company with a strong pipeline of oncology drugs. The stock price has declined as investors appeared to lock in some gains following a strong performance during the first half of the year. We believe Sino Biopharm's sustainable earnings growth profile will remain attractive over the long term due to its impressive drug pipeline and position to win business development deals to sell drugs in China produced by international pharmaceutical companies.

China Traditional Chinese Medicine is the largest manufacturer of traditional Chinese medicine (TCM) granules in the country. In August, the company provided first half results which showed the negative impact of COVID-19 on sales due to reduced patient traffic to public hospitals. If local virus transmissions remain near zero in China, we believe normal hospital patient traffic will recover during the rest of the year.

Volatility is to be expected in emerging markets—it's a natural part of what we believe is a superior growth opportunity over longer periods. As such, we will maintain our disciplined process and closely monitor positions—including calls with management teams—to adjust valuations and position size as we believe appropriate.

Investment Results (%)

As of 31 August 2020	Average Annual Total Returns								Linked Inception ²
	MTD	QTD	YTD	1 Yr	3 Yr	5 Yr	10 Yr	Inception	
Investor Class: ARTZX	1.97	12.39	0.42	12.68	3.57	11.37	2.64	0.46	
Linked Institutional and Investor Class¹									4.76
MSCI Emerging Markets Index	2.21	11.34	0.45	14.49	2.83	8.66	3.76	1.69	5.74

As of 30 June 2020	Average Annual Total Returns								Linked Inception ²
	MTD	QTD	YTD	1 Yr	3 Yr	5 Yr	10 Yr	Inception	
Investor Class: ARTZX	7.73	21.76	-10.65	-4.39	2.01	4.96	2.16	-0.50	
Linked Institutional and Investor Class¹									3.95
MSCI Emerging Markets Index	7.35	18.08	-9.78	-3.39	1.90	2.86	3.27	0.81	5.00

Source: Artisan Partners/MSCI. Returns for periods less than one year are not annualized. ¹Linked performance data shown relates to the Investor Shares from 2 June 2008 forward and for Institutional Shares prior to 2 June 2008. ²Institutional Class inception: 26 June 2006.

Performance of the Institutional Shares does not reflect higher expenses associated with the Investor Shares, and if reflected, would reduce the performance quoted. Past performance does not guarantee and is not a reliable indicator of future results. Investment returns and principal values will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than that shown. Call 800.344.1770 for current to most recent month-end performance. Performance may reflect agreements to limit a Fund's expenses, which would reduce performance if not in effect.

Portfolio Details

Net Asset Value (NAV)	\$16.60	
ARTZX Inception	2 June 2008	
Expense Ratios	Gross	Net ¹
Semi-Annual Report 31 Mar 2020 ^{2,3}	1.72%	1.35%
Prospectus 30 Sep 2019 ³	1.93%	1.35%

¹Net expenses reflect a contractual expense limitation agreement in effect through 31 Jan 2021. ²Unaudited, annualized for the six-month period. ³See prospectus for further details.

Top 10 Holdings (% of total portfolio)

Alibaba Group Holding Ltd (China)	11.7
Taiwan Semiconductor Manufacturing Co Ltd (Taiwan)	7.8
Samsung Electronics Co Ltd (Korea)	6.3
Reliance Industries Ltd (India)	3.7
Prosus NV (Netherlands)	3.6
Polyus PJSC (Russia)	3.5
MercadoLibre Inc (Argentina)	3.4
Sino Biopharmaceutical Ltd (China)	2.7
Samsung Biologics Co Ltd (Korea)	2.0
MediaTek Inc (Taiwan)	2.0
TOTAL	46.6%

Source: Artisan Partners. Portfolio country classifications are defined by the investment team.

Sector Diversification (% of total portfolio equities)

	Fund	MSCI EM ¹
Communication Services	6.0	12.9
Consumer Discretionary	25.9	19.8
Consumer Staples	2.6	6.3
Energy	6.0	5.6
Financials	16.0	17.8
Health Care	7.9	4.2
Industrials	8.2	4.5
Information Technology	20.4	17.5
Materials	6.5	7.1
Real Estate	0.0	2.4
Utilities	0.5	2.0
TOTAL	100.0%	100.0%

Source: Artisan Partners/GICS/MSCI. Cash and cash equivalents represented 1.7% of the total portfolio. ¹MSCI Emerging Markets Index.

Region/Country Allocation (% of total portfolio equities)

REGION	Fund	MSCI EM ¹
EMERGING ASIA	66.4	80.5
China	28.2	42.5
Taiwan	13.8	12.5
Korea	10.2	11.5
India	9.4	8.3
Indonesia	3.4	1.4
Malaysia	0.9	1.7
Thailand	0.4	1.9
EUROPE, MIDDLE EAST AND AFRICA	14.6	11.9
Russia	10.2	2.9
South Africa	1.9	3.5
Greece	1.5	0.1
Turkey	0.5	0.3
Saudi Arabia	0.4	2.6
LATIN AMERICA	13.1	7.5
Argentina	4.5	0.1
Brazil	4.0	4.8
Mexico	1.4	1.6
Peru	0.9	0.2
Chile	0.8	0.5
Colombia	0.7	0.2
Panama	0.7	—
DEVELOPED MARKETS	6.0	—
Netherlands	3.6	—
Hong Kong	1.8	—
Singapore	0.6	—
TOTAL	100.0%	100.0%

Source: Artisan Partners/MSCI. ¹MSCI Emerging Markets Index. Countries held in the index, but not held in the portfolio, are not listed. Portfolio country classifications are defined by the investment team and may differ substantially from MSCI classifications; index country classifications reflect MSCI methodology. For the portfolio's country breakdown according to MSCI methodology, refer to the Fund's most recent portfolio holdings at www.sec.gov.

Investment Team (Pictured left to right)



Portfolio Manager	Years of Investment Experience
Maria Negrete-Gruson, CFA	29
Analysts	
Meagan Nace, CFA	28
Chen Gu, CFA	32
Nicolas Rodriguez-Brizuela	21
Gurpreet Pal	16
Jessica Lin, CFA	15

Carefully consider the Fund's investment objective, risks and charges and expenses. This and other important information is contained in the Fund's prospectus and summary prospectus, which can be obtained by calling 800.344.1770. Read carefully before investing.

Current and future portfolio holdings are subject to risk. International investments involve special risks, including currency fluctuation, lower liquidity, different accounting methods and economic and political systems, and higher transaction costs. These risks typically are greater in emerging markets. Such risks include new and rapidly changing political and economic structures, which may cause instability; underdeveloped securities markets; and higher likelihood of high levels of inflation, deflation or currency devaluations. Securities of small- and medium-sized companies tend to have a shorter history of operations, be more volatile and less liquid and may have underperformed securities of large companies during some periods.

MSCI Emerging Markets Index measures the performance of emerging markets. The index(es) are unmanaged; include net reinvested dividends; do not reflect fees or expenses; and are not available for direct investment.

For the purpose of determining the Fund's holdings, securities of the same issuer are aggregated to determine the weight in the Fund. The discussion of portfolio holdings does not constitute a recommendation of any individual security. These holdings comprise the following percentages of the Fund's total net assets as of 31 Aug 2020: China Traditional Chinese Medicine Holdings Co Ltd 1.1%. Securities named in the Commentary, but not listed as a Top Ten Holding or not listed here are not held in the Fund as of the date of this report. The portfolio managers' views and portfolio holdings are subject to change and the Fund disclaims any obligation to advise investors of such changes.

Unless otherwise indicated, all information in this report includes all classes of shares, except performance and expense ratio information, and is as of the date shown in the upper right hand corner. Totals may not sum due to rounding.

This material is provided for informational purposes without regard to your particular investment needs. This material shall not be construed as investment or tax advice on which you may rely for your investment decisions. Investors should consult their financial and tax adviser before making investments in order to determine the appropriateness of any investment product discussed herein.

The Global Industry Classification Standard (GICS[®]) is the exclusive intellectual property of MSCI Inc. (MSCI) and Standard & Poor's Financial Services, LLC (S&P). Neither MSCI, S&P, their affiliates, nor any of their third party providers ("GICS Parties") makes any representations or warranties, express or implied, with respect to GICS or the results to be obtained by the use thereof, and expressly disclaim all warranties, including warranties of accuracy, completeness, merchantability and fitness for a particular purpose. The GICS Parties shall not have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of such damages.

MSCI makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used to create indices or financial products. This report is not approved or produced by MSCI.

Sector exposure percentages reflect sector designations as currently classified by GICS.

Artisan Partners Funds offered through Artisan Partners Distributors LLC (APDLLC), member FINRA. APDLLC is a wholly owned broker/dealer subsidiary of Artisan Partners Holdings LP. Artisan Partners Limited Partnership, an investment advisory firm and adviser to Artisan Partners Funds, is wholly owned by Artisan Partners Holdings LP.

© 2020 Artisan Partners. All rights reserved.

9/4/2020 A20695L_vR